2seventy Bio Stock EBITDA
| TSVT Stock | USD 3.61 0.45 14.24% |
2Seventy Bio fundamentals help investors to digest information that contributes to 2Seventy Bio's financial success or failures. It also enables traders to predict the movement of 2Seventy Stock. The fundamental analysis module provides a way to measure 2Seventy Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 2Seventy Bio stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -206.4 M | -216.7 M |
2Seventy | EBITDA |
2Seventy Bio Company EBITDA Analysis
2Seventy Bio's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current 2Seventy Bio EBITDA | (206.42 M) |
Most of 2Seventy Bio's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 2Seventy Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
2Seventy EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for 2Seventy Bio is extremely important. It helps to project a fair market value of 2Seventy Stock properly, considering its historical fundamentals such as EBITDA. Since 2Seventy Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of 2Seventy Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of 2Seventy Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
2Seventy Ebitda
Ebitda |
|
According to the company disclosure, 2Seventy Bio reported earnings before interest,tax, depreciation and amortization of (206.42 Million). This is 123.53% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 105.29% higher than that of the company.
2Seventy EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 2Seventy Bio's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 2Seventy Bio could also be used in its relative valuation, which is a method of valuing 2Seventy Bio by comparing valuation metrics of similar companies.2Seventy Bio is currently under evaluation in ebitda category among its peers.
2Seventy Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, 2Seventy Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to 2Seventy Bio's managers, analysts, and investors.Environmental | Governance | Social |
2Seventy Bio Institutional Holders
Institutional Holdings refers to the ownership stake in 2Seventy Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of 2Seventy Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing 2Seventy Bio's value.| Shares | Geode Capital Management, Llc | 2024-06-30 | 1.2 M | Dafna Capital Management Llc | 2024-06-30 | 1.1 M | State Street Corp | 2024-06-30 | 1 M | Eversept Partners, Llc | 2024-09-30 | 998.1 K | Cowen And Company, Llc | 2024-06-30 | 800 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 667 K | Bank Of America Corp | 2024-06-30 | 606.8 K | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 590 K | Jpmorgan Chase & Co | 2024-06-30 | 532.4 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 6.5 M | Kynam Capital Management, Lp | 2024-09-30 | 6 M |
2Seventy Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (2.07) % | ||||
| Operating Margin | (0.99) % | ||||
| Current Valuation | 218.07 M | ||||
| Shares Outstanding | 51.59 M | ||||
| Shares Owned By Insiders | 4.06 % | ||||
| Shares Owned By Institutions | 90.88 % | ||||
| Number Of Shares Shorted | 5.41 M | ||||
| Price To Book | 0.71 X | ||||
| Price To Sales | 3.57 X | ||||
| Revenue | 100.39 M | ||||
| Gross Profit | (183.46 M) | ||||
| EBITDA | (206.42 M) | ||||
| Net Income | (217.57 M) | ||||
| Cash And Equivalents | 357.93 M | ||||
| Cash Per Share | 9.45 X | ||||
| Total Debt | 256.67 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 3.88 X | ||||
| Book Value Per Share | 4.56 X | ||||
| Cash Flow From Operations | (166.86 M) | ||||
| Short Ratio | 23.15 X | ||||
| Earnings Per Share | (1.83) X | ||||
| Target Price | 8.25 | ||||
| Number Of Employees | 274 | ||||
| Beta | 1.79 | ||||
| Market Capitalization | 163.02 M | ||||
| Total Asset | 565.43 M | ||||
| Retained Earnings | (511.22 M) | ||||
| Working Capital | 177.99 M | ||||
| Net Asset | 565.43 M |
About 2Seventy Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 2Seventy Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 2Seventy Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 2Seventy Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for 2Seventy Stock Analysis
When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.